Caspofungin Dosing Regimen
For adult patients, administer caspofungin with a 70-mg loading dose on Day 1, followed by 50 mg once daily, with NO dose reduction required for moderate hepatic impairment (Child-Pugh B) despite FDA labeling recommendations. 1
Standard Adult Dosing by Indication
The FDA-approved dosing regimen varies by indication 1:
Candidemia and Other Candida Infections
- Loading dose: 70 mg IV on Day 1
- Maintenance: 50 mg IV once daily
- Duration: At least 14 days after last positive culture and resolution of symptoms
- Dose escalation: If 50 mg is well-tolerated but inadequate response, increase to 70 mg daily
Invasive Aspergillosis
- Loading dose: 70 mg IV on Day 1
- Maintenance: 50 mg IV once daily
- Duration: Based on disease severity, immunosuppression recovery, and clinical response
Esophageal Candidiasis
- No loading dose (not studied for this indication)
- Maintenance: 50 mg IV once daily
- Duration: 7-14 days after symptom resolution
Empirical Therapy in Febrile Neutropenia
- Loading dose: 70 mg IV on Day 1
- Maintenance: 50 mg IV once daily (escalate to 70 mg if inadequate response)
- Duration: Until neutropenia resolution; minimum 14 days after positive culture if fungal infection confirmed
Critical Hepatic Impairment Adjustments
This is where FDA labeling conflicts with recent high-quality evidence:
FDA Recommendations 1:
- Mild impairment (Child-Pugh A): No adjustment needed
- Moderate impairment (Child-Pugh B): Reduce to 35 mg daily (with 70-mg loading dose on Day 1)
- Severe impairment (Child-Pugh C): No clinical experience; use with extreme caution
Evidence-Based Reality:
Multiple recent pharmacokinetic studies demonstrate that dose reduction in Child-Pugh B or C cirrhosis results in subtherapeutic exposure 2, 3. A 2024 real-world study of 258 cirrhotic patients (67 Child-Pugh B, 191 Child-Pugh C) showed that standard-dose caspofungin (70 mg loading, 50 mg maintenance) was safe and effective, with 53.1% favorable response and no hepatic dysfunction exacerbation requiring dose adjustment 2.
Key finding: The Child-Pugh score does not correlate with caspofungin clearance in critically ill patients 4. Hypoalbuminemia (common in cirrhosis) actually increases clearance and volume of distribution, resulting in lower drug exposure—the opposite of what dose reduction would address 4.
Practical Recommendation:
Use full-dose caspofungin (70 mg loading, 50 mg maintenance) in Child-Pugh B or C cirrhosis unless true cirrhosis with portal hypertension is present 3. The 35-mg dose should be avoided as it leads to subtherapeutic exposure 3. This applies particularly to trauma- or sepsis-induced liver injury, where the Child-Pugh score is misleading 4.
Drug Interaction Adjustments
When caspofungin is co-administered with hepatic enzyme inducers 1:
Adults:
- Rifampin: Increase to 70 mg daily (no loading dose needed)
- Other inducers (efavirenz, nevirapine, carbamazepine, phenytoin, dexamethasone): Consider 70 mg daily
Pediatrics (3 months-17 years):
- Increase to 70 mg/m² daily (maximum 70 mg) with any enzyme inducer
Administration Details
- Infusion time: Approximately 1 hour 1
- Never give as IV bolus 1
- Reconstitution: Add 10.8 mL diluent to achieve 5 mg/mL (50-mg vial) or 7 mg/mL (70-mg vial) 1
Special Populations
Renal Impairment
No dose adjustment needed, including dialysis patients (caspofungin is not dialyzable) 1
Elderly (≥65 years)
No dose adjustment needed despite 28% increase in AUC—this is not clinically significant 1
Pediatric (3 months-17 years)
- Loading dose: 70 mg/m² on Day 1 (maximum 70 mg)
- Maintenance: 50 mg/m² daily (maximum 70 mg)
- Escalate to 70 mg/m² if inadequate response 1
Therapeutic Drug Monitoring
Consider TDM in high-risk populations 5:
- Target trough (Cmin) >1 mg/L per guideline recommendations 5
- Recent data suggests Cmin >3.58 μg/mL may optimize efficacy 6
- Particularly important in: critically ill patients, altered volume of distribution, severe hypoalbuminemia, obesity, treatment failure 5
Common Pitfalls to Avoid
- Do NOT reduce dose to 35 mg in Child-Pugh B cirrhosis despite FDA labeling—this creates subtherapeutic exposure 2, 3
- Do NOT use Child-Pugh score in sepsis/trauma-induced liver injury—it does not predict caspofungin clearance 4
- Do NOT forget the loading dose for candidemia, aspergillosis, or febrile neutropenia (but NOT for esophageal candidiasis) 1
- Body weight matters—lower weight correlates with higher concentrations; consider this in dosing decisions 6